Search

Displaying results 681 - 690 of 1101 in total
  1. Drug

    Triclocarban

    go.drugbank.com/drugs/DB11155
    Approved

    In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal

  2. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.

  3. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]

  4. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.

  5. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

  6. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for...

  7. Drug

    Oxtriphylline

    go.drugbank.com/drugs/DB01303
    Approved

    In the US, oxtriphylline is no longer available.

  8. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  9. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]

  10. Drug

    Metocurine iodide

    go.drugbank.com/drugs/DB00416
    ApprovedWithdrawn

    Metocurine Iodide is no longer available on the US market.